...
首页> 外文期刊>Cellular immunology >Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential
【24h】

Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential

机译:用来自急性髓性白血病(AML)或骨髓性消化术综合征(MDS)患者的白血病衍生的树突细胞(DC)刺激后T细胞的质量是对白血病细胞毒性潜力的预测性

获取原文
获取原文并翻译 | 示例
           

摘要

Myeloid leukemic cells can differentiate into leukemia-derived dendritic cells (DC leu), presenting known/unknown leukemic-antigens. Induced anti-leukemic T-cell-responses are variable. To further elicit DC/DC leu-induced T-cell-response-patterns we performed (functional)flow-cytometry/fluorolysis-assays before/after mixed lymphocyte cultures (MLC) of matched (allogeneic) donor-T-cells (n=6), T-cells prepared at relapse after stem cell transplantation (n=4) or (autologous) patients'-T-cells (n=7) with blast-containing-mononuclear-cells ('MNC') or DC leu-containing DC ('DC'). Compared to 'MNC' 'DC' were better mediators of anti-leukaemic T-cell-activity, although not in every case effective. We could define cut-off proportions of mature DC, DC leu, proliferating, CD4 +, CD8 + and non-naive T-cells after 'MNC'- or 'DC'-stimulation, that were predictive for an anti-leukemic-activity of stimulated T-cells as well as a response to immunotherapy. Interestingly especially ratios 1 of CD4:CD8 or CD45RO:CD45RA T-cells were predictive for anti-leukemic function after DC-stimulation.In summary the composition and quality of DC and T-cells after a MLC-stimulating-phase is predictive for a successful ex-vivo and in-vivo anti-leukemic response, especially with respect to proportions of proliferating, CD4 + and CD45RO + T-cells. Successful cytotoxicity and the development of a T-cell-memory after 'DC'-stimulation could be predictive for the clinical course of the disease and may pave the way to develop adoptive immunotherapy, especially for patients at relapse after SCT.
机译:髓性白血病细胞可以分化为白血病衍生的树突细胞(DC Leu),呈现已知的/未知的白血病 - 抗原。诱导抗白血病T细胞反应是可变的。进一步引发DC / DC Leu诱导的T细胞响应 - 响应模式(功能性)流式细胞术/氟解析/匹配(同种异体)供体-T细胞的混合淋巴细胞培养物(MLC)之前/氟解析(n = 6),在干细胞移植(n = 4)或(自体)患者-T-cell(n = 7)后复发后制备的T细胞,用含卤代单核细胞('MnC')或DC Leu-包含直流('DC')。与“MNC”DC'相比,抗白血病T细胞活性的更好介质,尽管在各种情况下都没有有效。我们可以定义成熟DC,DC Leu,增殖,CD4 +,CD8 +和非幼稚T细胞的截止比例,其在抗白血病活动中预测的预测性刺激的T细胞以及对免疫疗法的反应。有趣的是尤其是尤其是CD4:CD8或CD45RO的1:CD45RA T细胞在DC-治疗后抗白血病功能预测。发明内容MLC刺激相预测后DC和T细胞的组成和质量对于成功的前体内和体内抗白血病反应,特别是关于增殖,CD4 +和CD45RO + T细胞的比例。成功的细胞毒性和在DC'-刺激后的T细胞记忆的发育可能是对疾病的临床过程预测性,并且可以铺平道路发展的养老疗法,特别是对于SCT后复发的患者。

著录项

  • 来源
    《Cellular immunology》 |2010年第1期|共8页
  • 作者单位

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany;

    Municipal Hospital Oldenburg Germany;

    Department of Medicine II Municipal Hospital Augsburg Germany;

    University of Munich Department for Haematopoietic Transplantations Munich Germany Helmholtz;

    University of Munich Department for Haematopoietic Transplantations Munich Germany Helmholtz;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    Acute myeloid leukemia; Dendritic cells; Immunotherapy; Serum-free culture; Stem cell transplantation; T-cells;

    机译:急性髓性白血病;树突细胞;免疫疗法;无血清培养;干细胞移植;T细胞;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号